Chinese biotech company InventisBio raises $147m in Series D round
InventisBio, a Chinese biotech company focused on small molecule drugs, has raised $147 million in a Series D funding round. The funding round of the ... Read More
InventisBio licenses lung cancer drug D-0316 to Betta Pharma in RMB230m deal
In a significant development within the pharmaceutical industry, Shanghai-based InventisBio has entered into a strategic partnership with Betta Pharmaceuticals Co., Ltd. to co-develop the promising ... Read More